Vaccine Therapy in Curative Resected Prostate Cancer Patients

Inclusion Criteria: * Radical prostatectomy. Preferably accessible tumor tissue with enough volume and quality for vaccine production (extraction of tumor mRNA). * Pathological stage pT2 - pT3b and Gleason score 7B-10, pN0, pN+ or pNx. * Must be ambulatory with an ECOG performance status 0 or 1. * Tumor cells detected in bone-marrow samples (micrometastatic disease). Patients with Gleason score 9-10 or pT3b Gleason score 8 may also be included with negative bone-marrow aspiration. Bone-marrow aspirates and plasma for microRNA will be obtained before start of surgery. * Must be at least 18 years of age and less than 75 years. * PSA \< 0.2 µg/L within 6 weeks after surgery. * Must have lab values as the following: ANC ≥ 1.5 x 109/L; Platelets ≥ 100 x 109/L; Hb ≥ 9 g/dL (≥ 5.6 mmol/L); Creatinine ≤ 140 μmol/L (1.6 mg/dL)- if borderline, the creatinine clearance ≥ 40 mL/min; Bilirubin within the upper limit of normal; ASAT and ALAT ≤ 2.5 the upper limit of normal; Albumin levels above lower normal value * No metastasis on bone scans or MRI, last 3 months before inclusion. * Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH/GCP, and national/local regulations. Exclusion Criteria: * Previous treatment with LHRH (Luteinizing Hormone-Releasing Hormone) agonist. * Previous anti-androgen treatment (Casodex). * History of prior malignancy within the last 5 years, with the exception of curatively treated basal cell carcinoma. * Active infection requiring antibiotic therapy. * Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia. * Adverse reactions to vaccines such as asthma, anaphylaxis or other serious reactions. * History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, polymyositis-dermatomyositis, juvenile onset insulin dependent diabetes, or a vasculitic syndrome. * Positive testing for syphilis (treponema pallidum), HIV, Hepatitis B and C * Use of systemic glucocorticoids. * Any reason why, in the opinion of the investigator, the patient should not participate.